Entering text into the input field will update the search result below

AstraZeneca cut to Neutral at Credit Suisse; says valuation reflects oncology prospects

Sep. 15, 2022 12:22 PM ETAstraZeneca PLC (AZN) StockDSKYF, DSNKYBy: Dulan Lokuwithana, SA News Editor2 Comments

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

Credit Suisse downgraded AstraZeneca (NASDAQ:AZN) to Neutral from Outperform Thursday, arguing that the company shares, following a strong YTD performance, already reflect the company’s potential in oncology.

The analyst Dominic Lunn and the

Recommended For You

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC